摘要
目的对C群流行性脑膜炎多糖疫苗纯化工艺中的部分技术参数进行优化。方法采用L16(45)正交试验法试验,以纯化工艺中的1/10饱和中性醋酸钠溶液量(A)、冷酚的温度(B)、加冷酚的量(C)、冷酚提取的次数(D)为影响因素,以精多糖相对于CTAB-复合多糖的收率为指标,对C群流脑多糖疫苗纯化工艺条件进行遴选,并对优化工艺条件下所得的精多糖进行检定。结果收率高且各项指标合格的生产工艺条件最佳组合为A3B1C1D3。结论通过此纯化工艺的参数优化可得到较高的收率,且所得C群流脑多糖抗原的各项指标均符合国家标准。
Objective To optimize part technical parameters of the purification process of group C epidemic meningitis polysaccharide vaccine. Methods The L16 （45） orthogonal test method was used.With 1/10 saturated neutral sodium ac-etate solution amount （A）,temperature of cold phenol （B）,amount of cold phenol （C） and number of times of cold phenol extraction （D） in the purification process as the influencing factors and with the yield of refined polysaccharide to CTAB-compound polysaccharide as the indicator,the purification process conditions of group C epidemic meningitis polysaccharide vaccine was selected and the refined polysaccharide obtained under the purified process was measured. Results The optimal combination of the production process with the highest yield and eligible indicators was A3 B1 C1 D3. Conclusion Parameter optimization of the purification process can obtain high yield and all the indicator of the ob-tained group C epidemic meningitis polysaccharide antigens is accord with the national standard.
出处
《中国当代医药》
2015年第30期14-17,共4页
China Modern Medicine
关键词
C群流行性脑膜炎
多糖疫苗
纯化工艺
Group C epidemic meningitis
Polysaccharide vaccine
Purification process
